

- A
Cancelled*
355. A method according to Claim 354 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of from about 10^{-7} molar to about 10^{-5} molar.
356. A method according to Claim 355 wherein said targeting ligand exhibits a binding affinity (Kd) to the GPIIbIIIa receptor of about 10^{-6} molar.--

REMARKS**Status of the Claims**

Claims 100-103, 113-115, 122-124, 127 and 194-356 are pending in the application. Claims 1-99, 104-112, 116-121, 125-126, and 128-193 have been canceled. Claims 194-356 have been added. No claims have been amended.

Response to Restriction Requirement

A restriction has been required to one of seven groups of inventions, characterized as Groups I to VII. The claims of Group I (Claims 1-99, 116-121 and 125-126) are drawn to targeted compositions for imaging. Group II (Claims 100-103, 113-115, 122-124, and 127) is drawn to a therapeutic composition. Group III (Claims 104-105 and 108-111), Group IV (Claims 104 and 106) and Group V (Claims 104 and 107) are drawn to methods of preparing targeted compositions. The claims of Group VI (Claims 128 and 129) are directed to compounds having the formula specified in Claim 128. Claims of Group VII (Claims 170-193) are drawn to compounds having a hydrophobic moiety, a linking group, and a targeting agent.

Applicants hereby elect for prosecution the invention of Group II (Claims 100-103, 113-115, 122-124, and 127), which is characterized in the Office Action as being drawn to a therapeutic composition and the method of making and the method of delivering said composition.

Applicants further provisionally elect the species exemplified by a composition comprising (a) lipid vesicles formulated from one or more phospholipids, (b) perfluorobutane gas, (c) a targeting ligand which comprises a peptide including the amino acid sequence arginine-glycine-aspartic acid (RGD) and which targets (d) the glycoprotein GPIIbIIIa receptor. It is Applicants' understanding that this provisional election of species is being made to aid the Examiner in conducting a search and examination of the claimed subject matter, and is not to be construed as limiting the scope of Applicants' claims. It is also Applicants' understanding that, if the elected subject matter is found to be allowable over the prior art, the search and examination will be expanded to cover other species, until it includes the full scope of the generic claims included in the elected group.

The following Claims read on the elected species: Claims 100-103; 113-115; 122-124; 127; 194-203; 210-215^b; 217-238; 245-270; 277-303; 310-340; 347-356.

Applicants hereby affirm their right to file one or more divisional applications with respect to any of the non-elected subject matter.

The Amendment

The claims have been amended to conform with the subject matter of the elected invention. Added dependent claims 194-356 define preferred aspects of the invention, and are supported in the application, for example, in original dependent claims 4-32 and 78-83. The use of ultrasound energy to induce rupture of vesicles, as recited in Claims 326-356, is supported in the specification, for example on page 100, lines 7-8, and page 123, lines 26-28. The use of compositions directed to the GPIIbIIIa for targeting thromboses, as claimed, for example, in added Claims 328-356, is also supported in the application, for example on page 67, lines 3-5. The use of ultrasound energy to stimulate lysis of a thrombus, incorporated into the methods of added Claims 329-356, is also well supported in the application, for example on page 124, line 2, and page 96, lines 5-6.

CONCLUSION

Applicants believe that the foregoing constitutes a full and complete response to the Office Action of record. Accordingly, an early and favorable Action is requested respectfully.

Respectfully submitted,



S. Maurice Valla
Registration No. 43,966

Date: November 12, 1999

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100